TrialJournal of gastroenterology2020

Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial.

Morihisa Hirota et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.